Intercept Drops as FDA Refuses Speedy Approval of Liver Drug

(Bloomberg) -- Intercept Pharmaceuticals Inc. shares plummeted Monday as U.S. regulators dashed hopes for an accelerated approval of what investors thought would be the first medicine to treat tens...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.